||This article needs more medical references for verification or relies too heavily on primary sources. (January 2013)|
Transfer factors were originally described as immune molecules that are derived from blood or spleen cells that cause antigen-specific cell-mediated immunity, primarily delayed hypersensitivity and the production of lymphokines, as well as binding to the antigens themselves. They have a molecular weight of approximately 5000 Daltons and are composed entirely of amino acids. Transfer factors were discovered by Henry Sherwood Lawrence in 1955. Transfer factor has some promising findings as a target of immune research, but can only be considered an incompletely investigated field that has been essentially lost to history.
A second use of the term transfer factor applies to a likely different entity derived from cow colostrum or chicken egg yolk which is marketed as an oral dietary supplement under the same name citing claims of benefit to the immune system.
In 1942, Merrill Chase discovered that cells taken from the peritoneum of Guinea pigs that had been immunized against an antigen could transfer immunity when injected into Guinea pigs that had never been exposed to the antigen; this phenomenon was the discovery of cell-mediated immunity. Subsequent research attempted to uncover how the cells imparted their effects. Henry Sherwood Lawrence, in 1955, discovered that partial immunity could be transferred even when the immune cells had undergone lysis - indicating that cells did not need to be fully intact in order to produce immune effects. Dr. Lawrence went on to discover that only the factors less than 8000 Daltons were required to transfer this immunity; he termed these to be "transfer factors".
The history of cellular derived transfer factor as a treatment effectively ended in the early 1980s. While the research world was initially excited by the discovery of Dr Lawrence and the possibility that a small molecule could effect the immune system, the concept of small molecules having such profound biologic effect had not been proven. Despite several successes in using transfer factor to treat human disease and uncover immune effects, one then-prominent researcher was exposed for falsifying data related to his work on transfer factor and guinea pigs; effectively casting all of transfer factor science in a negative light. This scandal was followed shortly thereafter by the discovery of the Interleukin-1 alpha molecule and thus attention further shifted towards research on interleukins. By 1973, it was discovered that blood products could harbor viruses such as hepatitis A, indicating that transfer factor treatments derived from human or cow blood cells had the potential to transmit these diseases. With the eventual discovery of HIV/AIDS as an additional blood-borne disease most researchers viewed a product derived from blood as an unsafe treatment since screening for hepatitis B and HIV/AIDS would not be developed until after 1985. Some studies using transfer factor have been conducted after the discovery of HIV/AIDS, but almost all have been outside of the United States.
Transfer factor (immune molecule) scientific claims
Henry Sherwood Lawrence discovered that blood cells could 'transfer' antigen-specific cell-mediated immunity even after the cells had undergone lysis. This lymphocyte product is sometimes referred to as "dialyzable leukocyte extract" in the scientific literature due to being an extract from white blood cells undergoing dialysis to remove all molecules larger than ~5000 Daltons. Studies on cellular transfer factor have involved mostly animal models and small human clinical trials. These studies have demonstrated preliminary evidence of immune modulation as well as some clinical benefits in a handful of diseases, but the studies not been assessed beyond primary sources and the trials should only be considered pre-clinical.
Despite a small modicum of successes, transfer factor generated from human blood (human-derived), cow spleen (bovine-derived), or mouse spleen (murine derived) is not in routine clinical use today. A trial investigating its ability to immunize children with leukemia against shingles showed promise in a small number of patients, but represents only one of two placebo-controlled studies.
Human-derived transfer factor appears to be safe for use for up to two years and bovine-derived cellular transfer factor for up to three months. Side effects include fever and swelling and pain at the injection site. Concern has been raised over the possibility of catching Bovine spongiform encephalopathy (Mad Cow Disease) or other diseases from animal-derived products. Transfer factors are contraindicated for women who are pregnant or breastfeeding. Because human- and bovine-derived transfer factor are generated from blood cells they carry the potential for blood-borne disease such as HIV/AIDS and Hepatitis C
Transfer factor (dietary supplement) history, claims, and side effects
Colostrum is a form of milk produced by the mammary glands of mammals (including humans) in late pregnancy. It contains multiple immune modulating molecules including high antibody levels. Based on studies that are nearly three decades old noting an overlap in the observed in vitro effects between a molecule contained in colostrum called colostrinin and the dialyzable leukocyte extract mentioned above, a hypothesis formed that the two were the same. There has been no recent research investigations comparing the two entities and thus there is no verifiable evidence that either colostrum or egg whites do or do not contain the cellular product that shares the name transfer factor. The orally available transfer factor is not obtained from humans nor from blood products of any mammal or animal and thus does not carry the presumed risks of contracting blood borne or animal tissue derived diseases. Reports of safety with supplement use are only anecdotal. Retailers of dietary supplement transfer factors advice against use by those with an organ transplant or women that are pregnant or may become pregnant.
Colostrum/egg derived transfer factors have been promoted as a treatment for a large number of diseases and health concerns but have not been proven effective in the treatment of any of these conditions. The United States Food and Drug Administration regulates transfer factors as a dietary supplement and has issued a warning notice to a website selling transfer factors that they have not been proven to be effective or safe in the treatment of any condition, nor have there been any biological licenses or New Drug Applications produced for the substance.
- Kirkpatrick CH (June 1993). "Structural nature and functions of transfer factors". Ann. N. Y. Acad. Sci. 685: 362–8. doi:10.1111/j.1749-6632.1993.tb35889.x. PMID 8363241.
- Al-Askari, S (2009). "Henry Sherwood Lawrence". Biographical Memoirs, Volume 90. National Academy of Sciences. pp. 237–255. ISBN 0-309-12148-5.
- "Transfer Factor". WebMD. Retrieved 2010-02-16.
- PDR http://www.pdr.net/drugpages/productlabeling.aspx?mpcode=30651060
- Lawrence, H. S. (1955). "The Transfer in Humans of Delayed Skin Sensitivity to Streptococcal M Substance and to Tuberculin with Disrupted Leucocytes 12". Journal of Clinical Investigation 34 (2): 219–230. doi:10.1172/JCI103075. PMC 438618. PMID 13233344.
- Chedd, G (1974-12-26). "Transfer factor - Another scandal?". New Scientist 64 (929). pp. 920–1.
- Ojeda, M. O.; van't Veer, C.; Fernández Ortega, C. B.; Araña Rosainz, M. D. J.; Buurman, W. A. (2005). "Dialyzable Leukocyte Extract differentially regulates the production of TNFα, IL-6, and IL-8 in bacterial component-activated leukocytes and endothelial cells". Inflammation Research 54 (2): 74–81. doi:10.1007/s00011-004-1326-5. PMID 15750714.
- Wang, R. N.; Wang, Y. B.; Geng, J. W.; Guo, D. H.; Liu, F.; Chen, H. Y.; Zhang, H. Y.; Cui, B. A.; Wei, Z. Y. (2012). "Enhancing immune responses to inactivated porcine parvovirus oil emulsion vaccine by co-inoculating porcine transfer factor in mice". Vaccine 30 (35): 5246–5252. doi:10.1016/j.vaccine.2012.05.077. PMID 22705080.
- Berrón-Pérez, R.; Chávez-Sánchez, R.; Estrada-García, I.; Espinosa-Padilla, S.; Cortez-Gómez, R.; Serrano-Miranda, E.; Ondarza-Aguilera, R.; Pérez-Tapia, M.; Pineda Olvera, B.; Jiménez-Martínez Mdel, C.; Portugués, A.; Rodríguez, A.; Cano, L.; Pacheco, P. U.; Barrientos, J.; Chacón, R.; Serafín, J.; Mendez, P.; Monges, A.; Cervantes, E.; Estrada-Parra, S. (2007). "Indications, usage, and dosage of the transfer factor". Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 54 (4): 134–139. PMID 18297853.
- "Transfer Factor". WebMD. Retrieved 2010-02-16.
- Estrada-Parra, S.; Nagaya, A.; Serrano, E.; Rodriguez, O.; Santamaria, V.; Ondarza, R.; Chavez, R.; Correa, B.; Monges, A.; Cabezas, R.; Calva, C.; Estrada-Garcia, I. (1998). "Comparative study of transfer factor and acyclovir in the treatment of herpes zoster". International journal of immunopharmacology 20 (10): 521–535. doi:10.1016/S0192-0561(98)00031-9. PMID 9839657.
- Kirkpatrick, C. H. (2000). "Transfer factors: Identification of conserved sequences in transfer factor molecules". Molecular medicine (Cambridge, Mass.) 6 (4): 332–341. PMC 1949950. PMID 10949913.
- McConnell, et al. A comparison of IgG and IgG1 activity in an early milk concentrate from non-immunised cows and a milk from hyperimmunised animals. doi = 10.1016/S0963-9969(00)00163-0
- Wilson, G. B.; Poindexter, C.; Fort, J. D.; Ludden, K. D. (1988). "De novo initiation of specific cell-mediated immune responsiveness in chickens by transfer factor (specific immunity inducer) obtained from bovine colostrum and milk". Acta virologica 32 (1): 6–18. PMID 2897772.
- "Transfer Factor". Memorial Sloan–Kettering Cancer Center. 2009-10-08. Retrieved 2010-02-16.
- Barrett, S (2007-03-28). "Be Wary of Multiple Sclerosis "Cures"". Quackwatch. Retrieved 2010-02-12.
- Barrett, S (2005-06-02). "Warning Letter". Quackwatch. Retrieved 2010-02-12.